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DNA Self-Assembly of Targeted Near-Infrared-Responsive Gold
Nanoparticles for Cancer Thermo-Chemotherapy**
Zeyu Xiao, Changwei Ji, Jinjun Shi, Eric M. Pridgen, Jillian Frieder, Jun Wu, and
Omid C. Farokhzad*
The development of external stimulus-responsive nanoparti-
cle (NP) systems for cancer therapy has received considerable
attention in recent years, as these systems can differentially
increase drug accumulation at target cancer cells/tissues,
drastically decrease systemic toxicity, and potentially avoid
under- or over-dosing.
[1] External stimuli that have been
exploited for such applications include light,
[2] magnetic
field,
[3] ultrasound,
[4] and electricity.
[5] Among them, near-
infrared (NIR) light (650–900 nm) has recently become an
attractive stimulus because of its minimal absorbance by skin
and tissue, thus allowing for noninvasive and deep tissue
penetration.
[6] In particular, NIR light can be effectively
converted into heat by using photothermal NPs, such as gold
nanorods (NRs),
[7] gold nanoshells,
[8] hollow gold nano-
spheres,
[9] and carbon nanotubes.
[10] As such, NIR-responsive
NP platforms offer several important benefits for cancer
therapy. For example, NIR-induced local heating can be used
for cancer thermotherapy.
[11] In addition, NIR-responsive NP
delivery systems enable on-demand release of drugs for
cancer chemotherapy, presumably by heat-induced disruption
of the delivery vehicles.
[7,9b] Furthermore, the combination of
NIR-based thermotherapy and triggered chemotherapy
(thermo-chemotherapy) could provide higher therapeutic
efficacy than respective monotherapies.
[9b,12]
In addition to these advantages, investigators are explor-
ing the possibility of integrating active targeting ligands in
NIR-responsive NP platforms for targeted cancer thermo-
chemotherapy. This triple combination of thermotherapy,
triggered drug release, and targeted delivery, would achieve
optimal therapeutic efficacy in cancer treatment, relative to
pairwise combinations. For example, Lee et al.
[13] have
designed folate-conjugated, doxorubicin (Dox) loaded poly-
(lactic-co-glycolic acid) (PLGA)–gold half-shell NPs, and this
combination led to effective tumor elimination in target
tissues in a NIR-responsive manner. A current strategy in
formulating this targeted NIR-responsive NP requires multi-
ple steps, including 1) the synthesis of drug-loaded NPs,
2) deposition of gold compositions on NPs, and 3) post-
conjugation with targeting ligands followed by purification.
However, these complex processes could increase the diffi-
culty of adjusting bio-physicochemical properties of NPs in
a reproducible manner, and could contribute to unintended
drug release from NPs, thereby resulting in unfavorable
batch-to-batch variability in the characteristics of drug
loading. Alternatively, using pre-functionalized components
to self-assemble into targeted NPs would eliminate the need
for post-modification of NPs and is amenable to being scaled-
up with little batch-to-batch variability.
[14] This self-assembly
strategy has led to the clinical translation of first-in-man
targeted cyclodextrin-based NPs for small interfering RNA
(siRNA) delivery,
[15] and targeted PLGA-based NPs for
docetaxel delivery.
[16] Nevertheless, use of such a self-assem-
bly strategy in the design of targeted NIR-responsive NPs has
not been reported to date.
Inspired by nature and the ability of complimentary
strands of DNA to hybridize, we designed a DNA-based
platform that can self-assemble into targeted NIR-responsive
NPs for cancer therapy. As illustrated in Figure 1, this
platform comprises three distinct functional components:
complementary DNA strands, the gold NR (50 nm 10 nm),
and a polyethylene glycol (PEG) layer. The DNA strands,
which consist of sequential CG base pairs, provide loading
sites for Dox,
[17] a model chemotherapeutic drug. By changing
the number of CG base pairs, drug loading can be precisely
tuned. In addition to serving as drug-loading scaffold, one
strand of the DNA (termed capture strand) is thiolated for
gold NR capture, and the complementary strand (termed
targeting strand) is pre-conjugated with ligands for cell-
specific targeting. Gold NRs serve as the model NIR light-to-
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[18] and for denatur-
ing the DNA double helix upon NIR irradiation,
[19] leading to
the triggered release of loaded drugs at target site for
chemotherapy. The PEG layer allows the NPs to evade
recognition by the immune system and prolongs the circu-
lation half-life of the NPs.
[15] Most notably, the assembly of
this multifunctional platform can be achieved by DNA
hybridization in a single step, which contributes to the tunable
and predictable feature in targeting and drug loading.
Besides, these DNA-assembled NPs have a relatively small
size (about 10–100 nm), which could facilitate their extrava-
sation out of circulation at the tumor site
[20] and diffusion in
the tumor extracellular space,
[21] thus enhancing the anti-
tumor efficacy.
We first designed the DNA sequence with 24-base pair
(CGA)8/(TCG)8 for Dox loading, as this anti-cancer drug can
preferentially intercalate into double-stranded CG base
pair.
[17] Previous studies have shown that the fluorescence of
Dox can be quenched after intercalation into the CG base
pair;
[22] we used this finding to monitor the number of Dox
molecules loaded onto the designed 24-base-pair DNA
strands. Figure 2a shows a sequential decrease in the Dox
fluorescence intensity, when a fixed concentration of Dox was
incubated with an increasing molar ratio of the double-
stranded (CGA)8/(TCG)8. Ultimately, a maximum level of
fluorescence quenching was reached, indicating that the
loading capacity of the designed DNA sequence was 7.5
Dox per (CGA)8/(TCG)8 duplex.
We next synthesized and characterized the targeting
strands and the gold NR-conjugated capture strands. The
targeting strand was constructed by conjugating N-hydrox-
ysuccinimide (NHS) terminated (TCG)8 oligonucleotide
(ONT) with NH2-terminated PEG-folic acid (FA).
[23] The
anion exchange chromatography analysis (see Figure S1 in
the Supporting Information) confirmed the successful con-
jugation of (TCG)8-PEG-FA. Free (TCG)8 ONTwas eluted at
a retention time of 10.7 min, whereas the (TCG)8-PEG-FA
conjugate was eluted with two peaks at 8.7 and 8.9 min, which
represent the b and g carboxyl groups on FA, respectively.
[23]
The capture strand, which is complimentary to the targeting
strand, was constructed by modifying (CGA)8 ONT with
ethylene glycol-thiol at its 5’ end, wherein the thiol group can
capture the gold NR surface by the thiol–gold bond,
[24] and
the ethylene glycol segment can separate the alkanethiol from
the capture strand, and thus avoid possible steric hindrance
during the hybridization of capture/targeting strand.
[25] Nota-
bly, to minimize the aggregation and nonspecific protein
binding in vivo,
[26] the gold NR surface was pre-assembled
with a thiolated PEG layer, and then mixed with capture
strands to form gold NR-capture strand conjugates. To
quantify the surface coverage of the capture strands on gold
NRs, Cy3-labeled capture strands with different concentra-
tions were reacted with NRs, and a rinse cycle was followed to
remove the nonchemisorbed strands. The Cy3-labeled strands
chemisorbed on the NRs were then displaced by mercaptoe-
thanol,
[27] and were quantified using fluorescence spectrosco-
py by interpolation from a standard liner calibration curve.
Totally, about 72 capture strands were bound on each gold
NR (Figure S2).
NR-conjugated capture strands (ONT-NR) were mixed
with targeting strands, and DNA hybridization led to the
assembly of the targeted DNA gold NR (T-DNA-NR)
platform. Dynamic light scattering showed the T-DNA-NR
had a hydrodynamic size of 681 nm (Figure 2b), compared
to gold NR which had a hydrodynamic size of 462 nm (data
Figure 1. DNA assembly of a targeted, NIR-responsive delivery plat-
form. This platform comprises gold NRs (50 nm 10 nm), PEG layers,
and complementary DNA oligonucleotides consisting of capture
strands and targeting strands. Consecutive CG base pairs provide
binding sites for doxorubicin (Dox) loading. The capture strands are
conjugated to gold NRs for NIR response. The targeting strands are
complementary to the capture strands and conjugated with ligands for
molecular targeting. The delivery platform is assembled through the
hybridization of capture strands attached on the NRs and targeting
stands. The resulting double-stranded DNA structures form scaffolds
for Dox intercalation. Upon NIR irradiation, the heated gold NRs result
in DNA denaturation and the release of drugs (Dox) at the target site.
Figure 2. a) Fluorescence spectra of the Dox (1 mm) solution with
increasing molar ratio of hybridized DNA duplex (from top to bottom:
0, 0.10, 0.11, 0.13, 0.14, 0.16, 0.20, 0.25, 0.33, 0.50, and 1.00 equiv) at
an excitation of 480 nm. b) Hydrodynamic size distribution of T-DNA-
NR showing the mean value at 68 nm. c) Flow cytometry profile of
cellular binding and uptake of nontargeted ONT-NR-Cy3 (black line)
and targeted T-DNA-NR-Cy3 (red line) in KB cells. d) A representative
confocal image showing the cellular distribution of T-DNA-NR-Cy3.
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the cell-growth medium without a significant change in size
over a period of two days, indicating their potential for in vivo
applications.
To demonstrate the capacity of T-DNA-NR to interact
with target cells, we visualized the cellular binding and uptake
of Cy3-labeled T-DNA-NRs (T-DNA-NR-Cy3). Human
nasopharyngeal epidermoid carcinoma (KB) cells, which
overexpress folate receptors, were incubated at 378C for 2 h
with nontargeted ONT-NR-Cy3 and FA-targeted T-DNA-
NR-Cy3, and subsequently washed to remove unbound
bioconjugates. Compared with ONT-NR-Cy3, T-DNA-NR-
Cy3 showed a 10-fold increase in its binding and uptake
fluorescence profile, as evidenced by flow cytometric analysis
(Figure 2c). High-magnification confocal microscopy further
confirmed the effective uptake of the T-DNA-NR-Cy3 (Fig-
ure 2d). These results demonstrate the potenital of our T-
DNA-NRs for efficient targeted drug delivery.
Next, we loaded Dox onto the T-DNA-NR platform (T-
DNA(Dox)-NR) through intercalation with GC base pairs,
and examined its release upon NIR irradiation in vitro. Based
on the loading of 7.5 Dox molecules per hybridized
(TCG)8/(CGA)8 pair, and 72 copies of ONTs per NR, we
inferred that each T-DNA-NR can load about 576 Dox
molecules. The capablity of gold NRs to generate heat upon
NIR irradiation was examined by inserting the probe of
a thermometer into the medium with NRs. As shown in
Figure S3, the temperature of the medium increased and
reached about 808C at 2.5 min of irradiation (laser power:
600 mW), indicating the efficacy of the NRs to elevate the
temperature of surrounding envioronments. To study the Dox
release, KB cells were incubated with T-DNA (Dox)-NR for
2 h, and excess nanoconjugates were removed; T-DNA
(Dox)-NRs bound to or taken up into the target cells were
then exposed to NIR irradiation for 0, 5, and 10 min. The
fluorescence of Dox molecules was initially quenched
because of their intercalation into DNA helices. Upon NIR
illumination, the photothermal heating on the NR surface
caused the denaturation of DNA helices at their melting
temperature,
[19] leading to the release of Dox molecules into
the cells. The number of released Dox molecules, reflected by
the fluorescence of the whole cell, was assessed by flow
cytometry analysis (Figure 3a). Notably, a right shift of the
fluorescence profile was also observed in the sample that was
not NIR irradiated (NIR 0 min), attributable to unquenched
background Dox fluorescence and a few Dox molecules
liberated from the conjugates by diffusion during the 2 h of
incubation.
[22] Following 5 min of irradiation, the fluorescence
signal of the Dox molecules was observably increased,
indicating the partial release of the drug. After 10 min of
irradiation, most Dox molecules were liberated from the
DNA double helices, resulting in a distinct right shift of the
fluorescence profile.
We used 10 min as the optimized irradiation time, and
compared thetherapeuticeffectsof differentNPformulations
in vitro. KB cells were incubated with the same dose of ONT-
NR, T-DNA-NR, and T-DNA(Dox)-NR for 2 h, washed
twice, irradiated by NIR for 10 min, and further incubated
with fresh media for 48 h. Cell viability was evaluated by the
3-4,5-dimethylthiazol-2-yl-2,5-diphenyl tetrazolium bromide
(MTT) assay. As demonstrated in Figure 3b, T-DNA-NR
showed greater cytotoxicity than ONT-NR (34.373.03
versus 56.370.69, mean valuestandard deviation,
(meanSD), n=3, P<0.05), because of a higher amount
of FA-targeted T-DNA-NR bound to and internalized by KB
cells, compared to the amount of nontargeted ONT-NR. T-
DNA(Dox)-NR, which releases Dox molecules during NIR
irradiation, provided the highest cytotoxicity (10.770.57,
meanSD, n=3, P<0.05).
We proceeded to explore the capability of T-DNA(Dox)-
NR to respond to NIR stimuli and release of Dox molecules
in vivo. Previous studies suggest that NP attachment and Dox
intercalation markedly improves the stability and resistance
of nucleotides to enzyme degradation in vivo,
[28] which
allowed us to apply the T-DNA(Dox)-NR platform in vivo
without the requirement for degradation-resistant DNA
modification. Xenograft tumor models were developed by
injecting KB cells subcutaneous (s.c.) in the flank of BALB/c
nude mice. After the tumor size reached about 100 mm
3,
a single intratumoral injection of T-DNA(Dox)-NR was
administered, and 2 h later, the mice were divided into four
groups, and the tumor region was exposed to NIR laser light
for 0, 5, 10, or 15 min (4 mice per group). Each tumor was
then collected, frozen, and four 10 mm thick slices were taken
from the mid-cross section of the tumor tissue. Thus, a total of
16 slices were processed for statistical analysis in each group.
Because released Dox molecules can diffuse into the tumor
cells and yield red fluorescence, the average fluorescent
Figure 3. a) NIR-responsive Dox release from T-DNA(Dox)-NR in vitro.
Flow cytometry histogram profile of Dox fluorescence in KB cells upon
different NIR irradiation time. b) In vitro cell viability measured by
MTT assays. KB cells were incubated with ONT-NR, T-DNA-NR, and T-
DNA(Dox)-NR for 2 h. Cells were then washed, exposed to NIR for
10 min, and incubated additionally 48 h prior to the cell viability
measurement. *, P<0.05 by a two-sample student’s t-test.
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microscopy, was used as an indication of the amount of
released Dox molecules. Compared to the 0 min-irradiation
group, which shows the average fluorescence intensity at
19.454.79 (mean valuestandard error, (meanSE), n=
16), the 5 min-irradiation group showed a three-fold increase
in intensity (86.7825.46; meanSE, n=16, P<0.05); and
the 10 min- and 15 min-irradiation groups similarly showed
a 39-fold increase in intensity (757.30124.18 and 753.97
123.02, respectively; meanSE, n=16, P<0.001; Figure S4).
Representative histological sections were photographed to
document the differential Dox release upon different irradi-
ation times (Figure S4a), with a maximal release at 10 min.
Finally, to demonstrate the robust and reproducible
features of our NP platform, we evaluated its in vivo
anti-tumor efficacy in two folic receptor-overexpressed
tumor models (KB and HeLa). Subcutaneous tumors
were initiated in the flank of the BALB/c nude mice by
injecting one million KB or HeLa-Luciferase (HeLa-
Luc) cells. After the tumors had developed to about
100 mm
3, the drug efficacy was studied in four groups of
mice (n=7 per group), with weight and tumor size
differences minimized among the groups. Four regimens
(phosphate buffered saline (PBS), ONT-NR, T-DNA-
NR, and T-DNA(Dox)-NR) were administered by
a single intratumoral injection, with a low dose (1.5 
10
10 NR particles per mouse) in the KB tumor model
and a high dose (4.5 10
10 NR particles per mouse) in
the HeLa-Luc tumor model. Two hours post injection,
the tumor of each mouse was irradiated for 10 min
(600 mW, 808 nm), and tumor development was moni-
tored by measuring the tumor size (KB tumor model) or
by measuring bioluminescent imaging (HeLa-Luc
tumor model) at regular intervals for two weeks. In
the KB tumor model, the mean tumor volumes at
different days were calibrated by normalizing the initial
volume (at day 0) to 1 (Figure 4). At the end of the
experiment (day 14), the relative tumor volume of the
ONT-NR group was 3.930.40, that is, 24% less than
that of the PBS group (5.210.42). The relative tumor
volume of T-DNA-NR group was 2.520.58, 35% less than
that of the ONT-NR group; and the relative tumor volume of
the T-DNA (Dox)-NR group was 1.820.25, 28% less than
that of the T-DNA-NR group (meanSE, n=7, P<0.05).
For HeLa-Luc tumor model, the total bioluminescence
intensity (photons/sec) obtained from each tumor at different
days was calibrated by normalizing initial bioluminescence
signal (at day 0) to 1. The relative luminescence intensity
signal (meanSE, n=7) was then plotted as a function of
time (Figure 5), to indicate the time course of the tumor
growth. On day 12, the ONT-NR group showed a relative
signal of 6.040.88, 41% less than PBS group (10.182.88);
the T-DNA-NR group showed a relative signal of 1.980.49,
64% less than the ONT-NR group; and the T-DNA(Dox)-NR
group showed a relative signal of 0.580.26, 71% less than
the T-DNA-NR group. Consistent with previous observa-
tions,
[13,29] the treatment with ONT-NR delayed tumor growth
compared to treatments with PBS, due to the photothermal
ablation of cancer cells. Moreover, the T-DNA-NR group
showed significantly higher efficacy in tumor reduction
compared to ONT-NR group, presumalby because the FA
targeting property allows a higher amount of T-DNA-NRs to
bind to the cell surface and to be internalized by the KB/
HeLa-Luc cells, whereas the non-targeted ONT-NRs only
diffuse into the extracellular space between tumor cells, and
are endocytosed to a very limited extent. In addition, because
heat transfer from the surface of NRs to the surrounding
cellular environment is highly localized and decays exponen-
tially within a few nanometers,
[19a] targeted T-DNA-NRs,
which had a shorter distance to the cancer cell surface than
non-targeted ONT-NRs, led to an enhanced destruction of
Figure 4. Anti-tumor effects of various treatments on KB tumor-
bearing mice. ONT-NR, T-DNA-NR, and T-DNA(Dox)-NR were injected
intratumorally in a single dose (1.5 10
10 NR particles), followed by
10 min NIR irradiation or without NIR irradiation. The volumetric
changes in tumor size relative to that at day 0 are plotted over time
after irradiation. Data are presented as meanSE of seven mice per
group. *, P<0.05 by two-sample student’s t-test.
Figure 5. Anti-tumor efficacy of the NIR-responsive NP platform on HeLa-Luc
tumor-bearing mice. ONT-NR, T-DNA-NR, and T-DNA(Dox)-NR were injected
intratumorally in a single dose (4.5 10
10 NR particles), followed by 10 min of
NIR irradiation or without NIR irradiation. Images were taken at day 0, 1, 3, 5,
8, 10, and 12, respectively. The changes in luminescence intensity indicate the
tumor growth. a) Representative mice images showing the tumor progression
under different treatment conidtions. b) The tumor luciferase intensities
relative to day 0 are plotted over time after NIR irradiation. Data are presented
as meanSE of seven mice per group. *,P<0.05 by two-sample student’s t-
test.
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from T-DNA(Dox)-NRs subsequent to NIR irridiation con-
tributed to the additional chemotherapeutic efficacy of T-
DNA(Dox)-NRs in tumor reduction relative to T-DNA-NR
treatment alone. Notably, the T-DNA(Dox)-NR group with-
out NIR irradiation also demonstrated modest tumor reduc-
tion compared to the PBS group, presumbly because of the
gradual release of dox molecules from the intratumorally
injected T-DNA-NR complex overtime.
In summary, we have developed a targeted NIR-respon-
sive NP delivery platform by a simple DNA self-assembly
process. The in vitro and in vivo results demonstrate that this
platform selectively delivers anti-cancer drugs to target cells,
releases them upon NIR irradiation, and effectively inhibits
tumor growth through thermo-chemotherapy. Despite the use
of intratumoral injection of NPs in the current study, this local
delivery strategy serves as an initial step to test the efficacy of
our DNA-assembled NP platform, and further systematic
delivery of NPs will be explored to expand our findings. In
particular, our platform incorporates the targeting ligands
through a DNA-assembly process and loads drugs thereafter,
and thus the ligand density anddrug loading can be fine-tuned
and precisely controlled, which will facilitate the optimization
of NP bio-physicochemical properties to achieve optimal
biodistribution for systemic adminstration. We also anticipate
that the present system could be accommodated with differ-
ent therapeutics, and could be similarly incorporated with
other NIR transducers and disease-specific targeting ligands
for the treatments of a myriad of important human diseases.
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